NASDAQ:CTSO
Cytosorbents Corporation Stock News
$0.88
+0.0606 (+7.40%)
At Close: May 03, 2024
CytoSorbents Provides Preliminary Third Quarter Business Update and Revised 2021 Product Revenue Guidance
04:35pm, Tuesday, 12'th Oct 2021
MONMOUTH JUNCTION, N.J., Oct. 12, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using
MONMOUTH JUNCTION, N.J., Oct. 7, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using
CytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb® in Critically Ill Patients with COVID-19
09:25am, Tuesday, 14'th Sep 2021
MONMOUTH JUNCTION, N.J., Sept. 14, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery anno
A Trio of Stocks Growing Revenue Per Share Fast
11:02am, Monday, 13'th Sep 2021
The S&P 500 stocks saw their aggregate trailing 12-month real revenue per share grow at a compound annual growth rate of approximately 2.4% over the past five years. The share price of the benchmark i
CytoSorbents Commemorates World Sepsis Day and Sepsis Awareness Month with Key Sepsis-Related Events, Sponsorships and Studies
07:08am, Monday, 13'th Sep 2021
MONMOUTH JUNCTION, N.J., Sept. 13, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions, such as sepsis, in intensive care and car
MONMOUTH JUNCTION, N.J., Sept. 10, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery usin
CytoSorbents' Product Associated With High Survival In Critically Ill COVID-19 Patients
09:26am, Wednesday, 01'st Sep 2021
CytoSorbents Corporation (NASDAQ: CTSO) has announced topline results from its CytoSorb Therapy in COVID-19 (CTC) multicenter registry. The data were presented at the International Symposium on Int
CTSO Stock: Over 6% Increase Pre-Market Explanation
08:21am, Wednesday, 01'st Sep 2021
The stock price of CytoSorbents Corporation (NASDAQ: CTSO) increased by over 6% pre-market. This is why it happened.
MONMOUTH JUNCTION, N.J., Sept. 1, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using bl
CytoSorbents, Aferetica Launch Organ Perfusion System In Italy
11:57am, Monday, 30'th Aug 2021
CytoSorbents Corporation (NASDAQ: CTSO) and Aferetica srl (Italy) have launched products to remove inflammatory mediators at Italy's European Society of Organ Transplantation Congress. Aferetica'
MONMOUTH JUNCTION, N.J. and BOLOGNA, Italy, Aug. 30, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) and Aferetica srl (Italy), two pioneers in intensive care immunotherapy and blood pu
CytoSorbents' Antithrombotic Removal System Scores Second FDA Breakthrough Device Tag
10:07am, Thursday, 12'th Aug 2021
The FDA has granted a second Breakthrough Device designation to CytoSorbents Corporation's (NASDAQ: CTSO) DrugSorb-ATR Antithrombotic Removal System. The designation covers removing the Direct
MONMOUTH JUNCTION, N.J., Aug. 12, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using
CytoSorbents Q2 Earnings Lag Consensus, Higher Costs Weigh On Bottom Line
07:00am, Wednesday, 04'th Aug 2021
CytoSorbents Corporation (NASDAQ: CTSO) reported Q2 revenue of $12 million, up 23% Y/Y, but missing the consensus of $12.27 million. Product sales increased 19% Y/Y to $11.4 million.
CytoSorbents Corporation (CTSO) CEO Phillip Chan on Q2 2021 Results - Earnings Call Transcript
10:56pm, Tuesday, 03'rd Aug 2021
CytoSorbents Corporation (CTSO) CEO Phillip Chan on Q2 2021 Results - Earnings Call Transcript
